PT -期刊文章盟伊恩·f·洛克TI -药物- 10.1212 / WNL.49.1_Suppl_1罗匹尼罗的援助。S58 DP - 1997年7月01 TA -神经病首页学PG - S58 S62 VI 16 - 49 IP - 1 5 4099 - //www.ez-admanager.com/content/49/1_Suppl_1/S58.short 4100 - //www.ez-admanager.com/content/49/1_Suppl_1/S58.full所以Neurology1997 7月01;49 AB -使用多巴胺受体激动剂作为单药治疗或与左旋多巴治疗帕金森病(PD)允许或限制减少左旋多巴的剂量,可能推迟发病或减少电动机后期并发症的严重程度。Ropinirole is a new nonergoline dopamine agonist that binds specifically to D2-like receptors with a selectivity similar to that of dopamine (D3 > D2 > D4). The chemical structure of ropinirole has the potential to maintain a structure-activity relationship similar to that of dopamine and other effective dopamine agonists without producing ergot-related adverse effects. Ropinirole has demonstrated efficacy in two standard preclinical models of PD and has shown a very low propensity to induce dyskinesia in these studies. This latter property is of potential clinical importance for pharmacotherapy of early PD. This article will present the importance of pharmacologic specificity of dopamine agonists along with the basic pharmacologic characteristics of ropinirole that may contribute to its efficacy in the treatment of PD.